The pharmaceutical industry just launched an attack on this exclusive Biden program

Pharmaceutical companies and House Republicans have aligned to launch a full-scale attack on the new Medicare. drug reformsdepicting one of President Joe Biden’s signatures achievements and I have began to reduce prescription costs for the elderly.

He pharmaceutical industry is challenging a key component of the new prescription drug initiative in courtwhile a group that represents the majority house of republicans is calling for the repeal of the entire program through legislation. They argue that the reforms will reduce investment in research and development and ultimately lead to fewer innovative cures.

The legal challenge officially got a powerful new champion Wednesday when industry trade group PhRMA filed a lawsuit alleging that the most well-known feature of the new law violates the Constitution in multiple ways.

that arrangement gives the federal government authority to negotiate the price of a limited set of drugs in Medicare. Although seniors wouldn’t see reduced prices until 2026, the negotiation process begins in September, and PhRMA wants the courts to intervene before then.

PhRMA filed the lawsuit along with a couple of advocacy groups, he National Association of Infusion Centers and the World Colon Cancer Associationwhose representatives also appeared on a conference call Wednesday announcing the lawsuit.

Both groups include drug manufacturers among their corporate supportersand Democrats were quick to denounce the lawsuit as a ploy by the pharmaceutical industry to maximize profits at the expense of seniors struggling to pay what are the higher drug prices in the world.

“It’s no surprise that Big Pharma wants to prevent Medicare from negotiating lower drug prices on behalf of America’s seniors,” said the Senate Finance Chairman. Ron Wyden (D-Ore.) said Wednesday.

PhRMA lawsuit is fourth largest legal challenge to the new law. drug manufacturers Merck and bristol myers squibb have already filed lawsuits, as has the US Chamber of Commercea conservative group representing business interests.

The lawsuits differ on the details, but they take the same general approach, claiming that the new initiative exceeds the authority of Congress, and violates the rights of manufacturers, by effectively forcing drugmakers to sell their drugs at the prices it sets. the government and without sufficient procedural protections. .

“It is a government mandate disguised as negotiation”, PhRMA Summary states “Y is unconstitutional”.

Merck Summary is even more forceful, arguing that the new program is “tantamount to extortion.”

In the weeks since Merck filed that initial lawsuit, several Legal Experts they have said they believe the industry’s claims are weak, arguing, among other things, that manufacturers who are not happy with negotiated prices have the option of withdrawing from Medicare altogether.

“Participation is really lucrative for them, so they may not want to leave, and that’s fine, but it doesn’t mean they were coerced,” University of Michigan law professor. Nicholas Bagley he told HuffPost.

Whether the industry’s arguments prevail, as always, will depend on how individual legal scholars interpret the Constitution and precedents.

One of PhRMA’s more specific claims is that the new law delegate too much power to the executive branch. That argument could appeal to conservative justices, and eventually to conservative Supreme Court justices, who have been sympathetic to such arguments in other contexts.

But courts have long recognized the federal government’s authority to require health care providers, or manufacturers of medical products, to meet certain conditions if they want to sell their products to Medicare and its beneficiaries.

Asking judges to side with the industry in this case may mean asking them to overturn those precedents, or at least interpret them in a new way, and even some philosophically sympathetic judges may refuse.

PhRMA’s lawsuit comes a week after the Republican Study Committee, whose member list includes more than three-quarters of all House Republicans, called for repealing all new Medicare drug reforms.

That would mean eliminating not only negotiated prices, but also three features that the lawsuits do not challenge: a insulin limit prices, a new out-of-pocket limit for drugs, and sanctions in manufacturers that raise prices faster than inflation.

But there is no divergence between the industry and the Republicans when it comes to the impact of price negotiations, who say that reduce the profits of pharmaceutical companies enough for reduce investment that subscribes to the innovation.

“We remain very concerned about the impact this law will have on patients and future innovation,” PhRMA President Stephen Ubl said during a conference call Wednesday to announce the lawsuit.

To bolster their case, opponents of Democratic drug reform have been citing a industry funded study from a research organization called life transformation arguing that only a fraction of the latest drug breakthroughs would have reached the market if the new policies had been in place.

Other consultation groups, researchers and industry officials have made dire predictions of yours And during the conference call on Wednesday, Ubl said he is already listening to industry leaders who think the new regulations are deterring investment.

But if and how government intervention in drug prices really affects innovation It has been the subject of debate for a long time.

Many experts say fears of depressed innovation are misplaced, especially when it comes to the actual reforms that became law in 2022, given that the new law covers only a limited group of drugs in a limited set of circumstances.

He Congressional Budget Office predicted that the new reforms would reduce total drug production for only 1% during the first 30 years.

and a new paper that appeared in the newspaper Health Affairs Intern on Wednesday he noted that Biden and Democrats have passed additional legislation increasing the federal government’s overall support for basic scientific research. That might actually lead to more breakthroughs rather than fewer, the paper’s authors speculated.

As for warnings that drug reforms will discourage investors, ricardo frankdirector of the USC-Brookings Schaeffer Health Policy Initiative and a co-author of that new article, told HuffPost that he hasn’t seen any signs of diminishing earnings expectations in the financial reports he’s been reviewing recently.

“I just think that what they say in Congress and in the courts is very different from what they say on Wall Street,” Frank said.

New prescription drug reforms were part of the Inflation Reduction Lawthe landmark piece of national legislation that Democrats passed on a partisan vote in 2022 after more than a year of debate on Capitol Hill.

But the part of the legislation on the price of medicines was In the works for much longer than that.

An earlier, more ambitious version passed the House in 2019 when Democrats controlled the House but not the Senate or the White House. And the underlying concept of the federal government negotiating drug prices with manufacturers dates back to at least the 1990s when then-President Bill Clinton included such a proposal as part of his nefarious plan to create a universal coverage system.

That’s a common pattern with health care policy. Major legislative achievements, such as the creation of Medicare and Medicaid in 1965 and the enactment of the Affordable Care Act In 2010, decades of effort and struggle followed, and ultimately major compromises to get the votes needed for passage.

But the enactment has never represented the end of the debate. All of these programs faced continuous attacks, such as “obamacareHe did this for years as conservatives tried to get judges to strike down the law and Republicans tried to rally the votes to repeal it in Congress.

Medicare, Medicaid, and the Affordable Care Act survived in part because advocates spent a lot of time fighting to preserve them in the courts and in the public eye. Now it appears that the new prescription drug reforms face a similar existential threat, which means their survival may depend on a similarly effective defense.

“This legal action underscores how critical it is to have a president in the White House who will fight for lower healthcare costs for Americans,” Wyden said. “I am deeply concerned that a Republican administration will roll out the red carpet for Big Pharma and once again prohibit Medicare from negotiating lower drug prices.”

Proponents of the new program have a key asset: public support. Center consistently show that reforms are popular, even with republican voters. But to prevail in court, groups like PhRMA don’t have to win over the public. They only have to persuade a few judges.